Oppenheimer set a $176.00 price target on Jazz Pharmaceuticals (NASDAQ:JAZZ) in a report published on Monday, Stock Target Advisor reports. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.
Several other equities research analysts have also recently issued reports on JAZZ. HC Wainwright set a $12.00 price objective on shares of IMV and gave the stock a buy rating in a research report on Friday, May 10th. ValuEngine cut shares of Valero Energy from a hold rating to a sell rating in a research report on Wednesday, May 8th. Piper Jaffray Companies set a $202.00 price objective on shares of Jazz Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday, May 28th. SunTrust Banks began coverage on shares of Zoetis in a research report on Tuesday, March 19th. They set a hold rating and a $100.00 price objective for the company. Finally, Wells Fargo & Co reaffirmed a hold rating and set a $68.00 price objective (up from $65.00) on shares of Colgate-Palmolive in a research report on Monday, June 17th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have issued a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $179.41.
Shares of JAZZ stock opened at $138.23 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.15 and a quick ratio of 3.01. Jazz Pharmaceuticals has a 52 week low of $113.52 and a 52 week high of $181.46. The stock has a market cap of $7.99 billion, a PE ratio of 11.29, a PEG ratio of 1.18 and a beta of 1.15. The firm has a 50 day simple moving average of $134.65.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported $3.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.83 by $0.44. Jazz Pharmaceuticals had a net margin of 24.88% and a return on equity of 27.35%. The company had revenue of $508.19 million during the quarter, compared to analysts’ expectations of $466.55 million. During the same quarter last year, the company posted $2.98 EPS. The firm’s revenue was up 14.3% compared to the same quarter last year. On average, sell-side analysts predict that Jazz Pharmaceuticals will post 13.24 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in Jazz Pharmaceuticals in the first quarter valued at $25,000. Prime Capital Investment Advisors LLC purchased a new stake in Jazz Pharmaceuticals in the first quarter valued at $27,000. Carroll Financial Associates Inc. lifted its position in Jazz Pharmaceuticals by 166.7% in the first quarter. Carroll Financial Associates Inc. now owns 200 shares of the specialty pharmaceutical company’s stock valued at $28,000 after acquiring an additional 125 shares during the last quarter. Osborn Williams & Donohoe LLC purchased a new stake in Jazz Pharmaceuticals in the first quarter valued at $33,000. Finally, Moody National Bank Trust Division purchased a new stake in Jazz Pharmaceuticals in the first quarter valued at $40,000. 89.77% of the stock is owned by hedge funds and other institutional investors.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Recommended Story: Is a Roth IRA right for you?
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.